You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Bioelectronic Fusion Sensor System

    SBC: SENTIENT SCIENCE CORPORATION            Topic: N14AT019

    To address the Navy"s need for a common, scalable, platform for multi-modal 1pA level current sensing for Electrocardiogram (ECG), Electroencephalogram (EEG), and Electrodermal Response (EDR) to be fielded as a miniature wearable device with non-contact electrodes, Sentient and the State University of New York (SUNY) propose to develop the Bioelectronic Fusion Sensor System (BioFuSenS) that will a ...

    STTR Phase I 2014 Department of DefenseNavy
  2. Development of Characterization of Failure Modes for Mechanical Components

    SBC: Thornton Tomasetti, Inc.            Topic: N14AT011

    This proposal describes a new process to facilitate the shock qualification of submarine components, taking advantage of the similarities between readily observable design features of these components, and correlating them to success or failure in Navy shock qualification tests. To realize this Design Feature Similarity (DFS) approach, we will develop a set of criteria based on this type of readil ...

    STTR Phase I 2014 Department of DefenseNavy
  3. Development of a Micro-glider for Oceanographic Air-Sea Interaction Sampling

    SBC: Tusaire Incorporated            Topic: N14AT020

    Advanced effective Micro-glider development will be conceived under this Phase I effort.

    STTR Phase I 2014 Department of DefenseNavy
  4. Harvesting specific plant metabolites from hairy root cultures using magnetized n

    SBC: NAPROGENIX, INC.            Topic: NCCIH

    DESCRIPTION: Plants produce a wide variety of valuable bioactive metabolites, but these are commonly present in low concentrations in the wild-type plant. This makes the separation and purification of these compounds complicated and expensive. The applicant company, Naprogenix Inc, has developed a technology for increasing the yields of specific bioactive metabolites in mutant plant cell cultures ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Orally available transition state inhibitors for triple negative breast cancer

    SBC: NANOMETICS LLC            Topic: NCI

    Problem to be Solved: Triple-negative breast cancer (TNBC) is a deadly disease that accounts for 15-20% of all diagnosed breast cancers worldwide. Metastatic relapse of TNBC carries a poorer prognosis and lower survival rate compared to other breast cancersubtypes. Therefore, identifying novel targets and new therapeutics to treat patients diagnosed with TNBC remains a significant priority of the ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Novel Focal Adhesion Kinase autophosphorylation inhibitors against pancreatic cancer

    SBC: CUREFAKTOR PHARMACEUTICALS, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): Due to the absence of effective therapies, pancreatic cancer is the fourth leading cause of cancer deaths in both men and women. This study focuses on the development of new small molecule inhibitors targeting Focal Adhesion Kinase against pancreatic cancer. Focal Adhesion Kinase (FAK) has been shown to play an important role in tumor cell survival, including p ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Modified RNA tools and diagnostics for drug abuse

    SBC: ATHGHIN BIOTECHNOLOGY, INC.            Topic: NIDA

    DESCRIPTION (provided by applicant): Project Summary/Abstract RNA modifications are numerous, and range from simple methylation to complex changes such as addition of aminoacylcarbamoyl moieties. These modifications and, the levels at which are present, are emerging as important regulators of biological processes, and perturbations such as chemical or drug exposure can alter the patterns of specif ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Mitochondrial Uncoupling as a Therapeutic Target in Obesity

    SBC: Nano-Mite Technologies, LLC            Topic: NIDDK

    DESCRIPTION (provided by applicant): Obesity is recognized as a national and global epidemic, as approximately 65% of adults in the United States are classified as overweight or obese as defined by body mass index (BMI). In fact, in the year 2000, the human race reached a historical landmark, when for the first time in history the number of adults with excess weight surpassed the number of those w ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Hand Rehabilitation using Variable Assistance through Force and EMG Feedback

    SBC: Koronis Biomedical Technologies Corp.            Topic: NIA

    DESCRIPTION (provided by applicant): This project proposes to develop and evaluate a hand rehabilitation system for chronic hemiparetic stroke survivors that have lost their ability to full control their hand. Stroke is the leading cause of adult disability, and is the third leading cause of death in the United States. Stroke survivors often face a significant loss of functional motor control in ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Evaluation of TRB-N0224, a Proprietary Chemically-Modified Curumin, for the Treat

    SBC: TRAVERSE BIOSCIENCES, INC.            Topic: NIA

    DESCRIPTION (provided by applicant): Traverse Biosciences Inc. is a pre-clinical stage drug development company working to commercialize new chemical entities which act to resolve inflammatory conditions through pleiotropic host-modulation of pathologically unrestrained matrix metalloproteinases (MMPs) and pro-inflammatory cytokines. The company's lead drug candidate, TRB-N0224, is a proprie ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government